DaShenLin Pharmaceutical Group (603233) 주식 개요는 중국에서 의약품을 제조, 도매 및 소매하는 다센린 제약 그룹입니다. 자세히 보기603233 펀더멘털 분석스노우플레이크 점수가치 평가5/6미래 성장2/6과거 실적5/6재무 건전성5/6배당4/6강점공정 가치 추정치보다 낮은 57.5% 에서 거래수익은 매년 14.95% 증가할 것으로 예상됩니다.지난 1년간 수익이 31.8% 증가했습니다.분석가들은 주가가 37.9% 상승할 것이라는 데 동의합니다.위험 분석불안정한 배당 실적모든 위험 점검 보기603233 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW475,857 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA475,857 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥17.9116.2% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture045b2016201920222025202620282031Revenue CN¥45.1bEarnings CN¥2.1bAdvancedSet Fair ValueView all narrativesDaShenLin Pharmaceutical Group Co., Ltd. 경쟁사Yifeng Pharmacy ChainSymbol: SHSE:603939Market cap: CN¥29.1bLBX Pharmacy ChainSymbol: SHSE:603883Market cap: CN¥10.3bShuYu Civilian PharmacySymbol: SZSE:301017Market cap: CN¥5.8bYixintang Pharmaceutical GroupSymbol: SZSE:002727Market cap: CN¥6.9b가격 이력 및 성과DaShenLin Pharmaceutical Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CN¥17.9152주 최고가CN¥21.7852주 최저가CN¥14.39베타0.411개월 변동-6.96%3개월 변동-4.78%1년 변동5.11%3년 변동-36.71%5년 변동-46.69%IPO 이후 변동35.62%최근 뉴스 및 업데이트Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥17.05, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Consumer Retailing industry in China. Total loss to shareholders of 30% over the past three years.공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026Declared Dividend • Jun 21Dividend of CN¥0.49 announcedShareholders will receive a dividend of CN¥0.49. Ex-date: 26th June 2026 Payment date: 26th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 20% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공고 • Apr 24DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong ChinaReported Earnings • Apr 24First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: EPS: CN¥0.45 (up from CN¥0.40 in 1Q 2025). Revenue: CN¥6.97b (flat on 1Q 2025). Net income: CN¥511.1m (up 11% from 1Q 2025). Profit margin: 7.3% (up from 6.6% in 1Q 2025). Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 3.3%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings.공고 • Apr 23DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million on April 22, 2026. The consideration is CNY 51.73 million (all PRC stamp duties in relation to this transaction shall be borne by the Seller), representing the valuation of the target and target subsidiaries and subject to adjustment. The Consideration shall be paid by the Purchaser to the Seller in five instalments and subject to the special payment arrangement: The first instalment of CNY 4.674 million shall be paid to the Seller within 15 business days after the date of the Equity Transfer Agreement; second instalment of CNY 16.2362 million shall be paid to the Seller within 15 business days after completion of the changes to effect the Disposal, third instalment of CNY 17.0828 million shall be paid to the Seller within 15 business days after completion of operational handover matters and certain qualifications confirmed by the Purchaser, fourth instalment of CNY 2.46 million shall be paid to the Seller within 15 business days after delivery of operating systems and data to the Purchaser; and the fifth instalment of CNY 7.337 million shall be paid to the Seller within 15 business days after the earlier of (a) the first anniversary of the Closing Date; or (b) the second anniversary of the date of the equity transfer agreement. Pursuant to the Equity Transfer Agreement, an amount representing no more than 50% of the third instalment attributable to specific pharmacies may be withheld by the Purchaser and an additional CNY 3.94 million may be payable depending on the status of the lease agreement entered as prescribed by the equity transfer agreement. If any target subsidiaries are unable to operate normally following completion, the consideration shall be reduced by an amount equal to the attributed valuation of such target subsidiaries. In the event that the net assets of the target company at the closing date exceed the target net asset value of CNY 2.59 million, the consideration should be adjusted upwards to reflect the excess net asset, provided that net asset value at the closing date shall not exceed CNY 30 million and in any event, the total consideration (after any upward adjustment) shall not exceed CNY 79.14 million. As of March 31, 2026, Sipai Zhihe Technology (Guangzhou) Co., Ltd. reported total common equity of CNY 15.08 million. The completion of this transaction is contingent upon several key financial, operational, and structural conditions. Financially, the target company must maintain consolidated net assets of at least CNY 2.59 million and have accurate, compliant financial records. Operationally, all its subsidiaries must hold the necessary licenses and qualifications. Within 45 days after the date of the equity transfer agreement, the Reorganization should be completed and all of the target subsidiaries should become wholly-owned subsidiary of Sipai Zhihe Technology (Guangzhou) Co., Ltd. The net proceeds from the transaction will be applied for corporate purposes and as general working capital of the group. Ignite Capital Limited acted as financial advisor for Sipai Health.더 많은 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥17.05, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Consumer Retailing industry in China. Total loss to shareholders of 30% over the past three years.공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026Declared Dividend • Jun 21Dividend of CN¥0.49 announcedShareholders will receive a dividend of CN¥0.49. Ex-date: 26th June 2026 Payment date: 26th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 20% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공고 • Apr 24DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong ChinaReported Earnings • Apr 24First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: EPS: CN¥0.45 (up from CN¥0.40 in 1Q 2025). Revenue: CN¥6.97b (flat on 1Q 2025). Net income: CN¥511.1m (up 11% from 1Q 2025). Profit margin: 7.3% (up from 6.6% in 1Q 2025). Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 3.3%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings.공고 • Apr 23DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million on April 22, 2026. The consideration is CNY 51.73 million (all PRC stamp duties in relation to this transaction shall be borne by the Seller), representing the valuation of the target and target subsidiaries and subject to adjustment. The Consideration shall be paid by the Purchaser to the Seller in five instalments and subject to the special payment arrangement: The first instalment of CNY 4.674 million shall be paid to the Seller within 15 business days after the date of the Equity Transfer Agreement; second instalment of CNY 16.2362 million shall be paid to the Seller within 15 business days after completion of the changes to effect the Disposal, third instalment of CNY 17.0828 million shall be paid to the Seller within 15 business days after completion of operational handover matters and certain qualifications confirmed by the Purchaser, fourth instalment of CNY 2.46 million shall be paid to the Seller within 15 business days after delivery of operating systems and data to the Purchaser; and the fifth instalment of CNY 7.337 million shall be paid to the Seller within 15 business days after the earlier of (a) the first anniversary of the Closing Date; or (b) the second anniversary of the date of the equity transfer agreement. Pursuant to the Equity Transfer Agreement, an amount representing no more than 50% of the third instalment attributable to specific pharmacies may be withheld by the Purchaser and an additional CNY 3.94 million may be payable depending on the status of the lease agreement entered as prescribed by the equity transfer agreement. If any target subsidiaries are unable to operate normally following completion, the consideration shall be reduced by an amount equal to the attributed valuation of such target subsidiaries. In the event that the net assets of the target company at the closing date exceed the target net asset value of CNY 2.59 million, the consideration should be adjusted upwards to reflect the excess net asset, provided that net asset value at the closing date shall not exceed CNY 30 million and in any event, the total consideration (after any upward adjustment) shall not exceed CNY 79.14 million. As of March 31, 2026, Sipai Zhihe Technology (Guangzhou) Co., Ltd. reported total common equity of CNY 15.08 million. The completion of this transaction is contingent upon several key financial, operational, and structural conditions. Financially, the target company must maintain consolidated net assets of at least CNY 2.59 million and have accurate, compliant financial records. Operationally, all its subsidiaries must hold the necessary licenses and qualifications. Within 45 days after the date of the equity transfer agreement, the Reorganization should be completed and all of the target subsidiaries should become wholly-owned subsidiary of Sipai Zhihe Technology (Guangzhou) Co., Ltd. The net proceeds from the transaction will be applied for corporate purposes and as general working capital of the group. Ignite Capital Limited acted as financial advisor for Sipai Health.공고 • Mar 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026공고 • Dec 26DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026Reported Earnings • Oct 30Third quarter 2025 earnings: EPS exceeds analyst expectationsThird quarter 2025 results: EPS: CN¥0.25 (up from CN¥0.17 in 3Q 2024). Revenue: CN¥6.55b (up 2.5% from 3Q 2024). Net income: CN¥282.8m (up 41% from 3Q 2024). Profit margin: 4.3% (up from 3.1% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 39%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.공고 • Sep 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025Price Target Changed • Sep 01Price target increased by 7.4% to CN¥23.41Up from CN¥21.80, the current price target is an average from 7 analysts. New target price is 38% above last closing price of CN¥16.93. Stock is up 34% over the past year. The company is forecast to post earnings per share of CN¥1.07 for next year compared to CN¥0.81 last year.공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025Declared Dividend • Jun 15Dividend of CN¥0.31 announcedShareholders will receive a dividend of CN¥0.31. Ex-date: 19th June 2025 Payment date: 19th June 2025 Dividend yield will be 3.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (72% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has increased by an average of 16% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 68% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Major Estimate Revision • May 02Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥32.1b to CN¥29.3b. EPS estimate also fell from CN¥1.26 per share to CN¥1.07 per share. Net income forecast to grow 32% next year vs 52% growth forecast for Consumer Retailing industry in China. Consensus price target broadly unchanged at CN¥21.43. Share price rose 12% to CN¥18.92 over the past week.Reported Earnings • Apr 27Full year 2024 earnings released: EPS: CN¥0.81 (vs CN¥1.03 in FY 2023)Full year 2024 results: EPS: CN¥0.81 (down from CN¥1.03 in FY 2023). Revenue: CN¥26.5b (up 8.0% from FY 2023). Net income: CN¥914.8m (down 22% from FY 2023). Profit margin: 3.5% (down from 4.8% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공고 • Apr 26DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2025DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2025, at 10:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China공고 • Mar 28DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025분석 기사 • Mar 14We Think DaShenLin Pharmaceutical Group (SHSE:603233) Can Stay On Top Of Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Feb 14Potential Upside For DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Not Without RiskDaShenLin Pharmaceutical Group Co., Ltd.'s ( SHSE:603233 ) price-to-earnings (or "P/E") ratio of 20.5x might make it...공고 • Dec 27DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥16.98, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Consumer Retailing industry in China. Total loss to shareholders of 33% over the past three years.Reported Earnings • Nov 05Third quarter 2024 earnings: EPS misses analyst expectationsThird quarter 2024 results: EPS: CN¥0.17 (down from CN¥0.22 in 3Q 2023). Revenue: CN¥6.39b (up 11% from 3Q 2023). Net income: CN¥200.5m (down 22% from 3Q 2023). Profit margin: 3.1% (down from 4.5% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Major Estimate Revision • Nov 02Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥27.3b to CN¥26.9b. EPS estimate also fell from CN¥1.07 per share to CN¥0.921 per share. Net income forecast to grow 59% next year vs 61% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥21.18 to CN¥20.38. Share price rose 6.6% to CN¥15.94 over the past week.Price Target Changed • Oct 23Price target decreased by 11% to CN¥21.18Down from CN¥23.74, the current price target is an average from 9 analysts. New target price is 44% above last closing price of CN¥14.68. Stock is down 36% over the past year. The company is forecast to post earnings per share of CN¥1.07 for next year compared to CN¥1.03 last year.공고 • Sep 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024분석 기사 • Sep 30Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)DaShenLin Pharmaceutical Group Co., Ltd.'s ( SHSE:603233 ) price-to-earnings (or "P/E") ratio of 18.6x might make it...Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥14.81, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 47% over the past three years.Price Target Changed • Sep 20Price target decreased by 7.4% to CN¥23.74Down from CN¥25.63, the current price target is an average from 8 analysts. New target price is 90% above last closing price of CN¥12.48. Stock is down 51% over the past year. The company is forecast to post earnings per share of CN¥1.07 for next year compared to CN¥1.03 last year.Price Target Changed • Sep 11Price target decreased by 12% to CN¥25.63Down from CN¥29.11, the current price target is an average from 7 analysts. New target price is 100% above last closing price of CN¥12.80. Stock is down 51% over the past year. The company is forecast to post earnings per share of CN¥1.08 for next year compared to CN¥1.03 last year.Major Estimate Revision • Sep 06Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥29.1b to CN¥27.5b. EPS estimate also fell from CN¥1.24 per share to CN¥1.06 per share. Net income forecast to grow 56% next year vs 56% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥29.11 to CN¥27.63. Share price was steady at CN¥13.42 over the past week.분석 기사 • Sep 03DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their ModelsDaShenLin Pharmaceutical Group Co., Ltd. ( SHSE:603233 ) just released its latest quarterly report and things are not...Price Target Changed • Sep 02Price target decreased by 8.6% to CN¥27.91Down from CN¥30.54, the current price target is an average from 7 analysts. New target price is 121% above last closing price of CN¥12.65. Stock is down 51% over the past year. The company is forecast to post earnings per share of CN¥1.22 for next year compared to CN¥1.03 last year.New Risk • Sep 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.5% Last year net profit margin: 5.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (3.5% net profit margin).Reported Earnings • Sep 01Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: CN¥0.23 (down from CN¥0.38 in 2Q 2023). Revenue: CN¥6.59b (up 9.1% from 2Q 2023). Net income: CN¥259.1m (down 38% from 2Q 2023). Profit margin: 3.9% (down from 7.0% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.2%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.분석 기사 • Aug 20DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...공고 • Jun 28DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024Declared Dividend • Jun 19Dividend of CN¥0.31 announcedShareholders will receive a dividend of CN¥0.31. Ex-date: 21st June 2024 Payment date: 21st June 2024 Dividend yield will be 1.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 5.7% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 74% over the next 3 years, which should provide support to the dividend and adequate earnings cover.분석 기사 • Jun 17Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%DaShenLin Pharmaceutical Group Co., Ltd. ( SHSE:603233 ) shareholders that were waiting for something to happen have...Board Change • Jun 14Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. GM & Director Guoqiang Ke was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Jun 09Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • May 21Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?Key Insights Using the 2 Stage Free Cash Flow to Equity, DaShenLin Pharmaceutical Group fair value estimate is CN¥31.80...분석 기사 • May 06Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) EarningsSoft earnings didn't appear to concern DaShenLin Pharmaceutical Group Co., Ltd.'s ( SHSE:603233 ) shareholders over the...Major Estimate Revision • May 05Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥30.7b to CN¥29.5b. EPS estimate also fell from CN¥1.42 per share to CN¥1.23 per share. Net income forecast to grow 43% next year vs 54% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥33.79 to CN¥32.99. Share price rose 2.7% to CN¥21.78 over the past week.공고 • Apr 30DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2024DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2024, at 10:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong ChinaReported Earnings • Apr 29First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: EPS: CN¥0.35 (down from CN¥0.43 in 1Q 2023). Revenue: CN¥6.75b (up 14% from 1Q 2023). Net income: CN¥398.5m (down 20% from 1Q 2023). Profit margin: 5.9% (down from 8.4% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.분석 기사 • Apr 09Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...공고 • Mar 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024분석 기사 • Mar 17Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/EWith a price-to-earnings (or "P/E") ratio of 19.6x DaShenLin Pharmaceutical Group Co., Ltd. ( SHSE:603233 ) may be...공고 • Dec 29DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 30, 2024Reported Earnings • Nov 01Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: EPS: CN¥0.22 (up from CN¥0.18 in 3Q 2022). Revenue: CN¥5.73b (up 12% from 3Q 2022). Net income: CN¥256.9m (up 23% from 3Q 2022). Profit margin: 4.5% (up from 4.1% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 8.6%. Earnings per share (EPS) exceeded analyst estimates by 1.8%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 31Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: EPS: CN¥0.38 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥6.05b (up 20% from 2Q 2022). Net income: CN¥420.7m (up 28% from 2Q 2022). Profit margin: 7.0% (up from 6.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.8%. Earnings per share (EPS) exceeded analyst estimates by 2.0%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.공고 • Jun 28DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023Reported Earnings • Apr 28Full year 2022 earnings released: EPS: CN¥1.09 (vs CN¥0.83 in FY 2021)Full year 2022 results: EPS: CN¥1.09 (up from CN¥0.83 in FY 2021). Revenue: CN¥21.2b (up 27% from FY 2021). Net income: CN¥1.04b (up 31% from FY 2021). Profit margin: 4.9% (up from 4.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year.Price Target Changed • Jan 13Price target increased to CN¥49.60Up from CN¥45.10, the current price target is an average from 5 analysts. New target price is 15% above last closing price of CN¥43.19. Stock is up 21% over the past year. The company is forecast to post earnings per share of CN¥1.17 for next year compared to CN¥0.83 last year.Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥43.56, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.56 per share.Price Target Changed • Dec 19Price target increased to CN¥50.50Up from CN¥45.10, the current price target is an average from 4 analysts. New target price is 30% above last closing price of CN¥38.88. Stock is up 30% over the past year. The company is forecast to post earnings per share of CN¥1.25 for next year compared to CN¥0.83 last year.Price Target Changed • Nov 16Price target increased to CN¥45.10Up from CN¥41.56, the current price target is an average from 5 analysts. New target price is 6.1% above last closing price of CN¥42.52. Stock is up 39% over the past year. The company is forecast to post earnings per share of CN¥1.24 for next year compared to CN¥0.83 last year.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Price Target Changed • Nov 04Price target increased to CN¥45.10Up from CN¥41.56, the current price target is an average from 5 analysts. New target price is 22% above last closing price of CN¥36.88. Stock is up 12% over the past year. The company is forecast to post earnings per share of CN¥1.25 for next year compared to CN¥0.83 last year.Major Estimate Revision • Nov 03Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥20.6b to CN¥20.1b. EPS estimate also fell from CN¥1.18 per share to CN¥1.02 per share. Net income forecast to grow 39% next year vs 36% growth forecast for Consumer Retailing industry in China. Consensus price target broadly unchanged at CN¥41.76. Share price was steady at CN¥37.86 over the past week.Reported Earnings • Oct 28Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: EPS: CN¥0.22 (up from CN¥0.18 in 3Q 2021). Revenue: CN¥5.10b (up 19% from 3Q 2021). Net income: CN¥209.1m (up 21% from 3Q 2021). Profit margin: 4.1% (up from 4.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥35.54, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Consumer Retailing industry in China. Total returns to shareholders of 6.9% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥63.02 per share.Reported Earnings • Aug 31Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: CN¥0.34 (up from CN¥0.32 in 2Q 2021). Revenue: CN¥5.04b (up 26% from 2Q 2021). Net income: CN¥330.0m (up 8.2% from 2Q 2021). Profit margin: 6.5% (down from 7.6% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.2%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 24%, compared to a 17% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥34.11, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 18% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.63 per share.Valuation Update With 7 Day Price Move • May 26Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥32.53, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Consumer Retailing industry in China. Total returns to shareholders of 8.5% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥22.67 per share.Major Estimate Revision • May 04Consensus EPS estimates fall by 19%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥21.6b to CN¥21.1b. EPS estimate also fell from CN¥1.73 per share to CN¥1.41 per share. Net income forecast to grow 49% next year vs 29% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥66.90 to CN¥61.50. Share price rose 10% to CN¥26.40 over the past week.Price Target Changed • Apr 29Price target decreased to CN¥61.50Down from CN¥66.90, the current price target is an average from 7 analysts. New target price is 133% above last closing price of CN¥26.40. Stock is down 58% over the past year. The company is forecast to post earnings per share of CN¥1.69 for next year compared to CN¥1.00 last year.Reported Earnings • Apr 28Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: CN¥1.00 (down from CN¥1.35 in FY 2020). Revenue: CN¥16.8b (up 15% from FY 2020). Net income: CN¥791.2m (down 26% from FY 2020). Profit margin: 4.7% (down from 7.3% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) exceeded analyst estimates by 21%. Over the next year, revenue is forecast to grow 29%, compared to a 15% growth forecast for the retail industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Dec 31Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥42.11, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 27x in the Consumer Retailing industry in China. Total returns to shareholders of 110% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥21.44 per share.Price Target Changed • Nov 20Price target decreased to CN¥68.88Down from CN¥74.63, the current price target is an average from 11 analysts. New target price is 91% above last closing price of CN¥36.10. Stock is down 51% over the past year. The company is forecast to post earnings per share of CN¥1.33 for next year compared to CN¥1.35 last year.Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.35 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥4.30b (up 21% from 3Q 2020). Net income: CN¥172.7m (down 37% from 3Q 2020). Profit margin: 4.0% (down from 7.7% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Price Target Changed • Aug 30Price target decreased to CN¥80.38Down from CN¥88.70, the current price target is an average from 7 analysts. New target price is 80% above last closing price of CN¥44.60. Stock is down 38% over the past year.Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.41 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥4.00b (up 12% from 2Q 2020). Net income: CN¥305.1m (down 3.0% from 2Q 2020). Profit margin: 7.6% (down from 8.8% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 11Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥47.25, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥90.11 per share.Price Target Changed • Jun 11Price target decreased to CN¥73.93Down from CN¥88.72, the current price target is an average from 9 analysts. New target price is 38% above last closing price of CN¥53.57. Stock is down 8.2% over the past year.Reported Earnings • Apr 20Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥1.12 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥14.6b (up 31% from FY 2019). Net income: CN¥1.06b (up 51% from FY 2019). Profit margin: 7.3% (up from 6.3% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year whereas the company’s share price has increased by 22% per year.Valuation Update With 7 Day Price Move • Apr 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥71.75, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 27x in the Consumer Retailing industry in China. Total returns to shareholders of 88% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥66.96 per share.Is New 90 Day High Low • Mar 09New 90-day low: CN¥75.58The company is down 10.0% from its price of CN¥83.73 on 09 December 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.96 per share.Price Target Changed • Feb 03Price target raised to CN¥107Up from CN¥99.63, the current price target is an average from 10 analysts. The new target price is 10% above the current share price of CN¥96.59. As of last close, the stock is up 102% over the past year.Is New 90 Day High Low • Jan 25New 90-day high: CN¥105The company is up 22% from its price of CN¥85.99 on 27 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥64.40 per share.Valuation Update With 7 Day Price Move • Jan 18Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥91.98, the stock is trading at a trailing P/E ratio of 58.8x, up from the previous P/E ratio of 49.6x. This compares to an average P/E of 35x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 206%.Price Target Changed • Jan 08Price target raised to CN¥92.35Up from CN¥82.52, the current price target is an average from 7 analysts. The new target price is 18% above the current share price of CN¥78.34. As of last close, the stock is up 75% over the past year.Is New 90 Day High Low • Jan 04New 90-day low: CN¥76.99The company is down 7.0% from its price of CN¥82.46 on 30 September 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.94 per share.Is New 90 Day High Low • Dec 20New 90-day low: CN¥78.69The company is down 2.0% from its price of CN¥80.30 on 21 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.94 per share.Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥1.01b, up 50% from the prior year. Total revenue was CN¥13.6b over the last 12 months, up 28% from the prior year.공고 • Oct 29DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 31, 2020DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2020 results on Oct 31, 2020Is New 90 Day High Low • Oct 29New 90-day high: CN¥92.06The company is up 20% from its price of CN¥76.50 on 31 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥49.33 per share.공고 • Jul 10DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2020 results on Aug 28, 2020주주 수익률603233CN Consumer RetailingCN 시장7D2.3%2.5%0.2%1Y5.1%-17.6%9.7%전체 주주 수익률 보기수익률 대 산업: 603233은 지난 1년 동안 -17.6%의 수익을 기록한 CN Consumer Retailing 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 603233은 지난 1년 동안 9.7%를 기록한 CN 시장보다 저조한 성과를 냈습니다.주가 변동성Is 603233's price volatile compared to industry and market?603233 volatility603233 Average Weekly Movement6.1%Consumer Retailing Industry Average Movement6.0%Market Average Movement7.3%10% most volatile stocks in CN Market12.5%10% least volatile stocks in CN Market4.4%안정적인 주가: 603233는 지난 3개월 동안 CN 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 603233의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트199941,141Guoqiang Kewww.dslyy.com다센린 제약 그룹은 중국에서 의약품을 제조, 도매 및 소매하는 회사입니다. 중국 및 서양 특허 의약품, 인삼 강장제 약재 및 한약재, 건강 관리 제품, 의료 장비 및 기타 상품을 제공합니다. 이 회사는 1999년에 설립되었으며 중국 광저우에 본사를 두고 있습니다.더 보기DaShenLin Pharmaceutical Group Co., Ltd. 기초 지표 요약DaShenLin Pharmaceutical Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?603233 기초 통계시가총액CN¥20.40b순이익 (TTM)CN¥1.29b매출 (TTM)CN¥27.52b15.9x주가수익비율(P/E)0.7x주가매출비율(P/S)603233는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표603233 손익계산서 (TTM)매출CN¥27.52b매출원가CN¥18.03b총이익CN¥9.49b기타 비용CN¥8.20b순이익CN¥1.29b최근 보고된 실적Mar 31, 2026다음 실적 발표일Aug 25, 2026주당순이익(EPS)1.13총이익률34.49%순이익률4.67%부채/자본 비율33.3%603233의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당5.5%현재 배당 수익률74%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/15 16:05종가2026/08/14 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스DaShenLin Pharmaceutical Group Co., Ltd.는 15명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Qianyi LiChina International Capital Corporation LimitedBinbin ZhangCitic Securities Co., Ltd.Zhijie ZhaoCLSA12명의 분석가 더 보기
Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥17.05, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Consumer Retailing industry in China. Total loss to shareholders of 30% over the past three years.
공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026
Declared Dividend • Jun 21Dividend of CN¥0.49 announcedShareholders will receive a dividend of CN¥0.49. Ex-date: 26th June 2026 Payment date: 26th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 20% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공고 • Apr 24DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China
Reported Earnings • Apr 24First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: EPS: CN¥0.45 (up from CN¥0.40 in 1Q 2025). Revenue: CN¥6.97b (flat on 1Q 2025). Net income: CN¥511.1m (up 11% from 1Q 2025). Profit margin: 7.3% (up from 6.6% in 1Q 2025). Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 3.3%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings.
공고 • Apr 23DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million on April 22, 2026. The consideration is CNY 51.73 million (all PRC stamp duties in relation to this transaction shall be borne by the Seller), representing the valuation of the target and target subsidiaries and subject to adjustment. The Consideration shall be paid by the Purchaser to the Seller in five instalments and subject to the special payment arrangement: The first instalment of CNY 4.674 million shall be paid to the Seller within 15 business days after the date of the Equity Transfer Agreement; second instalment of CNY 16.2362 million shall be paid to the Seller within 15 business days after completion of the changes to effect the Disposal, third instalment of CNY 17.0828 million shall be paid to the Seller within 15 business days after completion of operational handover matters and certain qualifications confirmed by the Purchaser, fourth instalment of CNY 2.46 million shall be paid to the Seller within 15 business days after delivery of operating systems and data to the Purchaser; and the fifth instalment of CNY 7.337 million shall be paid to the Seller within 15 business days after the earlier of (a) the first anniversary of the Closing Date; or (b) the second anniversary of the date of the equity transfer agreement. Pursuant to the Equity Transfer Agreement, an amount representing no more than 50% of the third instalment attributable to specific pharmacies may be withheld by the Purchaser and an additional CNY 3.94 million may be payable depending on the status of the lease agreement entered as prescribed by the equity transfer agreement. If any target subsidiaries are unable to operate normally following completion, the consideration shall be reduced by an amount equal to the attributed valuation of such target subsidiaries. In the event that the net assets of the target company at the closing date exceed the target net asset value of CNY 2.59 million, the consideration should be adjusted upwards to reflect the excess net asset, provided that net asset value at the closing date shall not exceed CNY 30 million and in any event, the total consideration (after any upward adjustment) shall not exceed CNY 79.14 million. As of March 31, 2026, Sipai Zhihe Technology (Guangzhou) Co., Ltd. reported total common equity of CNY 15.08 million. The completion of this transaction is contingent upon several key financial, operational, and structural conditions. Financially, the target company must maintain consolidated net assets of at least CNY 2.59 million and have accurate, compliant financial records. Operationally, all its subsidiaries must hold the necessary licenses and qualifications. Within 45 days after the date of the equity transfer agreement, the Reorganization should be completed and all of the target subsidiaries should become wholly-owned subsidiary of Sipai Zhihe Technology (Guangzhou) Co., Ltd. The net proceeds from the transaction will be applied for corporate purposes and as general working capital of the group. Ignite Capital Limited acted as financial advisor for Sipai Health.
Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥17.05, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Consumer Retailing industry in China. Total loss to shareholders of 30% over the past three years.
공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026
Declared Dividend • Jun 21Dividend of CN¥0.49 announcedShareholders will receive a dividend of CN¥0.49. Ex-date: 26th June 2026 Payment date: 26th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 20% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공고 • Apr 24DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China
Reported Earnings • Apr 24First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: EPS: CN¥0.45 (up from CN¥0.40 in 1Q 2025). Revenue: CN¥6.97b (flat on 1Q 2025). Net income: CN¥511.1m (up 11% from 1Q 2025). Profit margin: 7.3% (up from 6.6% in 1Q 2025). Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 3.3%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings.
공고 • Apr 23DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million on April 22, 2026. The consideration is CNY 51.73 million (all PRC stamp duties in relation to this transaction shall be borne by the Seller), representing the valuation of the target and target subsidiaries and subject to adjustment. The Consideration shall be paid by the Purchaser to the Seller in five instalments and subject to the special payment arrangement: The first instalment of CNY 4.674 million shall be paid to the Seller within 15 business days after the date of the Equity Transfer Agreement; second instalment of CNY 16.2362 million shall be paid to the Seller within 15 business days after completion of the changes to effect the Disposal, third instalment of CNY 17.0828 million shall be paid to the Seller within 15 business days after completion of operational handover matters and certain qualifications confirmed by the Purchaser, fourth instalment of CNY 2.46 million shall be paid to the Seller within 15 business days after delivery of operating systems and data to the Purchaser; and the fifth instalment of CNY 7.337 million shall be paid to the Seller within 15 business days after the earlier of (a) the first anniversary of the Closing Date; or (b) the second anniversary of the date of the equity transfer agreement. Pursuant to the Equity Transfer Agreement, an amount representing no more than 50% of the third instalment attributable to specific pharmacies may be withheld by the Purchaser and an additional CNY 3.94 million may be payable depending on the status of the lease agreement entered as prescribed by the equity transfer agreement. If any target subsidiaries are unable to operate normally following completion, the consideration shall be reduced by an amount equal to the attributed valuation of such target subsidiaries. In the event that the net assets of the target company at the closing date exceed the target net asset value of CNY 2.59 million, the consideration should be adjusted upwards to reflect the excess net asset, provided that net asset value at the closing date shall not exceed CNY 30 million and in any event, the total consideration (after any upward adjustment) shall not exceed CNY 79.14 million. As of March 31, 2026, Sipai Zhihe Technology (Guangzhou) Co., Ltd. reported total common equity of CNY 15.08 million. The completion of this transaction is contingent upon several key financial, operational, and structural conditions. Financially, the target company must maintain consolidated net assets of at least CNY 2.59 million and have accurate, compliant financial records. Operationally, all its subsidiaries must hold the necessary licenses and qualifications. Within 45 days after the date of the equity transfer agreement, the Reorganization should be completed and all of the target subsidiaries should become wholly-owned subsidiary of Sipai Zhihe Technology (Guangzhou) Co., Ltd. The net proceeds from the transaction will be applied for corporate purposes and as general working capital of the group. Ignite Capital Limited acted as financial advisor for Sipai Health.
공고 • Mar 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026
공고 • Dec 26DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026
Reported Earnings • Oct 30Third quarter 2025 earnings: EPS exceeds analyst expectationsThird quarter 2025 results: EPS: CN¥0.25 (up from CN¥0.17 in 3Q 2024). Revenue: CN¥6.55b (up 2.5% from 3Q 2024). Net income: CN¥282.8m (up 41% from 3Q 2024). Profit margin: 4.3% (up from 3.1% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 39%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
공고 • Sep 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025
Price Target Changed • Sep 01Price target increased by 7.4% to CN¥23.41Up from CN¥21.80, the current price target is an average from 7 analysts. New target price is 38% above last closing price of CN¥16.93. Stock is up 34% over the past year. The company is forecast to post earnings per share of CN¥1.07 for next year compared to CN¥0.81 last year.
공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
Declared Dividend • Jun 15Dividend of CN¥0.31 announcedShareholders will receive a dividend of CN¥0.31. Ex-date: 19th June 2025 Payment date: 19th June 2025 Dividend yield will be 3.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (72% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has increased by an average of 16% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 68% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Major Estimate Revision • May 02Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥32.1b to CN¥29.3b. EPS estimate also fell from CN¥1.26 per share to CN¥1.07 per share. Net income forecast to grow 32% next year vs 52% growth forecast for Consumer Retailing industry in China. Consensus price target broadly unchanged at CN¥21.43. Share price rose 12% to CN¥18.92 over the past week.
Reported Earnings • Apr 27Full year 2024 earnings released: EPS: CN¥0.81 (vs CN¥1.03 in FY 2023)Full year 2024 results: EPS: CN¥0.81 (down from CN¥1.03 in FY 2023). Revenue: CN¥26.5b (up 8.0% from FY 2023). Net income: CN¥914.8m (down 22% from FY 2023). Profit margin: 3.5% (down from 4.8% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공고 • Apr 26DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2025DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2025, at 10:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China
공고 • Mar 28DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
분석 기사 • Mar 14We Think DaShenLin Pharmaceutical Group (SHSE:603233) Can Stay On Top Of Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Feb 14Potential Upside For DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Not Without RiskDaShenLin Pharmaceutical Group Co., Ltd.'s ( SHSE:603233 ) price-to-earnings (or "P/E") ratio of 20.5x might make it...
공고 • Dec 27DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥16.98, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Consumer Retailing industry in China. Total loss to shareholders of 33% over the past three years.
Reported Earnings • Nov 05Third quarter 2024 earnings: EPS misses analyst expectationsThird quarter 2024 results: EPS: CN¥0.17 (down from CN¥0.22 in 3Q 2023). Revenue: CN¥6.39b (up 11% from 3Q 2023). Net income: CN¥200.5m (down 22% from 3Q 2023). Profit margin: 3.1% (down from 4.5% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Nov 02Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥27.3b to CN¥26.9b. EPS estimate also fell from CN¥1.07 per share to CN¥0.921 per share. Net income forecast to grow 59% next year vs 61% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥21.18 to CN¥20.38. Share price rose 6.6% to CN¥15.94 over the past week.
Price Target Changed • Oct 23Price target decreased by 11% to CN¥21.18Down from CN¥23.74, the current price target is an average from 9 analysts. New target price is 44% above last closing price of CN¥14.68. Stock is down 36% over the past year. The company is forecast to post earnings per share of CN¥1.07 for next year compared to CN¥1.03 last year.
공고 • Sep 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024
분석 기사 • Sep 30Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)DaShenLin Pharmaceutical Group Co., Ltd.'s ( SHSE:603233 ) price-to-earnings (or "P/E") ratio of 18.6x might make it...
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥14.81, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 47% over the past three years.
Price Target Changed • Sep 20Price target decreased by 7.4% to CN¥23.74Down from CN¥25.63, the current price target is an average from 8 analysts. New target price is 90% above last closing price of CN¥12.48. Stock is down 51% over the past year. The company is forecast to post earnings per share of CN¥1.07 for next year compared to CN¥1.03 last year.
Price Target Changed • Sep 11Price target decreased by 12% to CN¥25.63Down from CN¥29.11, the current price target is an average from 7 analysts. New target price is 100% above last closing price of CN¥12.80. Stock is down 51% over the past year. The company is forecast to post earnings per share of CN¥1.08 for next year compared to CN¥1.03 last year.
Major Estimate Revision • Sep 06Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥29.1b to CN¥27.5b. EPS estimate also fell from CN¥1.24 per share to CN¥1.06 per share. Net income forecast to grow 56% next year vs 56% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥29.11 to CN¥27.63. Share price was steady at CN¥13.42 over the past week.
분석 기사 • Sep 03DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their ModelsDaShenLin Pharmaceutical Group Co., Ltd. ( SHSE:603233 ) just released its latest quarterly report and things are not...
Price Target Changed • Sep 02Price target decreased by 8.6% to CN¥27.91Down from CN¥30.54, the current price target is an average from 7 analysts. New target price is 121% above last closing price of CN¥12.65. Stock is down 51% over the past year. The company is forecast to post earnings per share of CN¥1.22 for next year compared to CN¥1.03 last year.
New Risk • Sep 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.5% Last year net profit margin: 5.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (3.5% net profit margin).
Reported Earnings • Sep 01Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: CN¥0.23 (down from CN¥0.38 in 2Q 2023). Revenue: CN¥6.59b (up 9.1% from 2Q 2023). Net income: CN¥259.1m (down 38% from 2Q 2023). Profit margin: 3.9% (down from 7.0% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.2%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
분석 기사 • Aug 20DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
공고 • Jun 28DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024
Declared Dividend • Jun 19Dividend of CN¥0.31 announcedShareholders will receive a dividend of CN¥0.31. Ex-date: 21st June 2024 Payment date: 21st June 2024 Dividend yield will be 1.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 5.7% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 74% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
분석 기사 • Jun 17Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%DaShenLin Pharmaceutical Group Co., Ltd. ( SHSE:603233 ) shareholders that were waiting for something to happen have...
Board Change • Jun 14Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. GM & Director Guoqiang Ke was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Jun 09Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
분석 기사 • May 21Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?Key Insights Using the 2 Stage Free Cash Flow to Equity, DaShenLin Pharmaceutical Group fair value estimate is CN¥31.80...
분석 기사 • May 06Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) EarningsSoft earnings didn't appear to concern DaShenLin Pharmaceutical Group Co., Ltd.'s ( SHSE:603233 ) shareholders over the...
Major Estimate Revision • May 05Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥30.7b to CN¥29.5b. EPS estimate also fell from CN¥1.42 per share to CN¥1.23 per share. Net income forecast to grow 43% next year vs 54% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥33.79 to CN¥32.99. Share price rose 2.7% to CN¥21.78 over the past week.
공고 • Apr 30DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2024DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2024, at 10:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China
Reported Earnings • Apr 29First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: EPS: CN¥0.35 (down from CN¥0.43 in 1Q 2023). Revenue: CN¥6.75b (up 14% from 1Q 2023). Net income: CN¥398.5m (down 20% from 1Q 2023). Profit margin: 5.9% (down from 8.4% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
분석 기사 • Apr 09Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
공고 • Mar 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024
분석 기사 • Mar 17Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/EWith a price-to-earnings (or "P/E") ratio of 19.6x DaShenLin Pharmaceutical Group Co., Ltd. ( SHSE:603233 ) may be...
공고 • Dec 29DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 30, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: EPS: CN¥0.22 (up from CN¥0.18 in 3Q 2022). Revenue: CN¥5.73b (up 12% from 3Q 2022). Net income: CN¥256.9m (up 23% from 3Q 2022). Profit margin: 4.5% (up from 4.1% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 8.6%. Earnings per share (EPS) exceeded analyst estimates by 1.8%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 31Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: EPS: CN¥0.38 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥6.05b (up 20% from 2Q 2022). Net income: CN¥420.7m (up 28% from 2Q 2022). Profit margin: 7.0% (up from 6.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.8%. Earnings per share (EPS) exceeded analyst estimates by 2.0%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
공고 • Jun 28DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023
Reported Earnings • Apr 28Full year 2022 earnings released: EPS: CN¥1.09 (vs CN¥0.83 in FY 2021)Full year 2022 results: EPS: CN¥1.09 (up from CN¥0.83 in FY 2021). Revenue: CN¥21.2b (up 27% from FY 2021). Net income: CN¥1.04b (up 31% from FY 2021). Profit margin: 4.9% (up from 4.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year.
Price Target Changed • Jan 13Price target increased to CN¥49.60Up from CN¥45.10, the current price target is an average from 5 analysts. New target price is 15% above last closing price of CN¥43.19. Stock is up 21% over the past year. The company is forecast to post earnings per share of CN¥1.17 for next year compared to CN¥0.83 last year.
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥43.56, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.56 per share.
Price Target Changed • Dec 19Price target increased to CN¥50.50Up from CN¥45.10, the current price target is an average from 4 analysts. New target price is 30% above last closing price of CN¥38.88. Stock is up 30% over the past year. The company is forecast to post earnings per share of CN¥1.25 for next year compared to CN¥0.83 last year.
Price Target Changed • Nov 16Price target increased to CN¥45.10Up from CN¥41.56, the current price target is an average from 5 analysts. New target price is 6.1% above last closing price of CN¥42.52. Stock is up 39% over the past year. The company is forecast to post earnings per share of CN¥1.24 for next year compared to CN¥0.83 last year.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Price Target Changed • Nov 04Price target increased to CN¥45.10Up from CN¥41.56, the current price target is an average from 5 analysts. New target price is 22% above last closing price of CN¥36.88. Stock is up 12% over the past year. The company is forecast to post earnings per share of CN¥1.25 for next year compared to CN¥0.83 last year.
Major Estimate Revision • Nov 03Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥20.6b to CN¥20.1b. EPS estimate also fell from CN¥1.18 per share to CN¥1.02 per share. Net income forecast to grow 39% next year vs 36% growth forecast for Consumer Retailing industry in China. Consensus price target broadly unchanged at CN¥41.76. Share price was steady at CN¥37.86 over the past week.
Reported Earnings • Oct 28Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: EPS: CN¥0.22 (up from CN¥0.18 in 3Q 2021). Revenue: CN¥5.10b (up 19% from 3Q 2021). Net income: CN¥209.1m (up 21% from 3Q 2021). Profit margin: 4.1% (up from 4.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥35.54, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Consumer Retailing industry in China. Total returns to shareholders of 6.9% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥63.02 per share.
Reported Earnings • Aug 31Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: CN¥0.34 (up from CN¥0.32 in 2Q 2021). Revenue: CN¥5.04b (up 26% from 2Q 2021). Net income: CN¥330.0m (up 8.2% from 2Q 2021). Profit margin: 6.5% (down from 7.6% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.2%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 24%, compared to a 17% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥34.11, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 18% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.63 per share.
Valuation Update With 7 Day Price Move • May 26Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥32.53, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Consumer Retailing industry in China. Total returns to shareholders of 8.5% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥22.67 per share.
Major Estimate Revision • May 04Consensus EPS estimates fall by 19%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥21.6b to CN¥21.1b. EPS estimate also fell from CN¥1.73 per share to CN¥1.41 per share. Net income forecast to grow 49% next year vs 29% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥66.90 to CN¥61.50. Share price rose 10% to CN¥26.40 over the past week.
Price Target Changed • Apr 29Price target decreased to CN¥61.50Down from CN¥66.90, the current price target is an average from 7 analysts. New target price is 133% above last closing price of CN¥26.40. Stock is down 58% over the past year. The company is forecast to post earnings per share of CN¥1.69 for next year compared to CN¥1.00 last year.
Reported Earnings • Apr 28Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: CN¥1.00 (down from CN¥1.35 in FY 2020). Revenue: CN¥16.8b (up 15% from FY 2020). Net income: CN¥791.2m (down 26% from FY 2020). Profit margin: 4.7% (down from 7.3% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) exceeded analyst estimates by 21%. Over the next year, revenue is forecast to grow 29%, compared to a 15% growth forecast for the retail industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Dec 31Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥42.11, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 27x in the Consumer Retailing industry in China. Total returns to shareholders of 110% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥21.44 per share.
Price Target Changed • Nov 20Price target decreased to CN¥68.88Down from CN¥74.63, the current price target is an average from 11 analysts. New target price is 91% above last closing price of CN¥36.10. Stock is down 51% over the past year. The company is forecast to post earnings per share of CN¥1.33 for next year compared to CN¥1.35 last year.
Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.35 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥4.30b (up 21% from 3Q 2020). Net income: CN¥172.7m (down 37% from 3Q 2020). Profit margin: 4.0% (down from 7.7% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Aug 30Price target decreased to CN¥80.38Down from CN¥88.70, the current price target is an average from 7 analysts. New target price is 80% above last closing price of CN¥44.60. Stock is down 38% over the past year.
Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.41 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥4.00b (up 12% from 2Q 2020). Net income: CN¥305.1m (down 3.0% from 2Q 2020). Profit margin: 7.6% (down from 8.8% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥47.25, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥90.11 per share.
Price Target Changed • Jun 11Price target decreased to CN¥73.93Down from CN¥88.72, the current price target is an average from 9 analysts. New target price is 38% above last closing price of CN¥53.57. Stock is down 8.2% over the past year.
Reported Earnings • Apr 20Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥1.12 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥14.6b (up 31% from FY 2019). Net income: CN¥1.06b (up 51% from FY 2019). Profit margin: 7.3% (up from 6.3% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year whereas the company’s share price has increased by 22% per year.
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥71.75, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 27x in the Consumer Retailing industry in China. Total returns to shareholders of 88% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥66.96 per share.
Is New 90 Day High Low • Mar 09New 90-day low: CN¥75.58The company is down 10.0% from its price of CN¥83.73 on 09 December 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.96 per share.
Price Target Changed • Feb 03Price target raised to CN¥107Up from CN¥99.63, the current price target is an average from 10 analysts. The new target price is 10% above the current share price of CN¥96.59. As of last close, the stock is up 102% over the past year.
Is New 90 Day High Low • Jan 25New 90-day high: CN¥105The company is up 22% from its price of CN¥85.99 on 27 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥64.40 per share.
Valuation Update With 7 Day Price Move • Jan 18Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥91.98, the stock is trading at a trailing P/E ratio of 58.8x, up from the previous P/E ratio of 49.6x. This compares to an average P/E of 35x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 206%.
Price Target Changed • Jan 08Price target raised to CN¥92.35Up from CN¥82.52, the current price target is an average from 7 analysts. The new target price is 18% above the current share price of CN¥78.34. As of last close, the stock is up 75% over the past year.
Is New 90 Day High Low • Jan 04New 90-day low: CN¥76.99The company is down 7.0% from its price of CN¥82.46 on 30 September 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.94 per share.
Is New 90 Day High Low • Dec 20New 90-day low: CN¥78.69The company is down 2.0% from its price of CN¥80.30 on 21 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.94 per share.
Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥1.01b, up 50% from the prior year. Total revenue was CN¥13.6b over the last 12 months, up 28% from the prior year.
공고 • Oct 29DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 31, 2020DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2020 results on Oct 31, 2020
Is New 90 Day High Low • Oct 29New 90-day high: CN¥92.06The company is up 20% from its price of CN¥76.50 on 31 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥49.33 per share.
공고 • Jul 10DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2020 results on Aug 28, 2020
